Marker shortfall and adulteration signals in a '5% withanolides' ashwagandha capsule
A 500 mg hard-shell capsule marketed as 'Ashwagandha root extract 5% withanolides' carries a label claim of 5% w/w total withanolides by HPLC. A contract laboratory reports: withanolide A 0.9% and withaferin A 1.1% (total 2.0% w/w); total ash 14.2%; acid-insoluble ash 3.8%; loss on drying 9.0%; lead 6.2 ppm; and an HPTLC fingerprint showing an intense band at Rf 0.62 that is absent from the authenticated Withania somnifera root reference, plus a weak band matching leaf. The supplier's certificate of analysis claims 5.1%. The company wants to release the batch of 1.2 million capsules on the supplier's CoA alone and to keep the '5%' claim on the ground that 'the assay is only a marker assay'. The same capsules are sold in India as an Ayurvedic proprietary medicine and exported as a dietary supplement.
1. Assess whether the batch meets its label claim and identify the most probable causes of the analytical profile. Which findings point to leaf-derived material and which to inorganic adulteration?
Read the worked answer
The batch fails on the label claim and the failure is not marginal: 2.0% total marker content against a 5% claim is a 60% shortfall, and no reasonable interpretation of a marker assay closes that gap. Either the supplier's 5.1% result is wrong or fabricated, the sample submitted is not representative, or the two laboratories use different reference standards and calculation bases. The first action is a supplier audit and re-test of a statistically drawn sample with a fully validated method, using withanolide A and withaferin A reference standards and reporting both individual and total content.
The pattern of the two markers is informative. Withaferin A occurs in both root and leaf, but the leaf is much richer in it, so a withaferin A-to-withanolide A ratio greater than one (here 1.1:0.9), together with a band matching leaf and a strong unidentified band at Rf 0.62, is consistent with leaf material or another species being blended in rather than pure root. The ash data point in a different direction, to inorganic adulteration. Neither explanation accounts for everything, and that is itself a finding: more than one problem is likely, which makes a single-cause explanation from the supplier implausible.
2. What do the ash and acid-insoluble ash data tell you, and what confirmatory tests would you order before release or rejection?
Read the worked answer
A total ash of 14.2% with acid-insoluble ash of 3.8% is far outside any reasonable pharmacopoeial limit for a Withania root extract; the acid-insoluble fraction is essentially silica, so this is sand, soil or a siliceous diluent either present on poorly washed raw drug or added. An extract will usually give a higher ash than the raw drug because soluble matter is removed and minerals concentrate, so raw material and declared excipients must be tested before the extract alone is blamed.
Confirmatory work: ash on the raw material and on the capsule contents; acid-insoluble residue with microscopic examination for sand, calcium oxalate and starch; X-ray fluorescence or ICP-MS for the elemental profile; sieve analysis; and a check of declared excipients. Ash is not the only problem. Loss on drying of 9.0% is high for a hygroscopic extract and predicts caking and microbial risk; lead at 6.2 ppm is within a 10 ppm limit but close enough to need a confirmatory ICP-MS result and a supplier trend; pesticide residues and aflatoxins should be added for an Indian herbal raw material.
Release or rejection is a specification decision, not a bench judgement. If the specification has limits for ash, moisture, heavy metals and marker content, three of them fail, and the batch is rejected on data rather than on suspicion.
3. The company wants to rely on the supplier's CoA and keep the claim. Argue the regulatory and scientific position, and propose the specification you would write.
Read the worked answer
Two questions are being conflated: what the product legally is, and what the label may claim. In India, an extract of a pharmacopoeial herb presented in a capsule with a therapeutic claim is a drug; if it is a proprietary Ayurvedic medicine it requires the appropriate manufacturing licence, must comply with the Ayurvedic Pharmacopoeia and labelling rules, and the claim must be supported by the approved formulation. If the same capsule is exported as a dietary supplement it is regulated as a food in that market, but it cannot be sold in India as a food while carrying a drug-like therapeutic claim; the regulatory route must match the claim and the market.
On the science, relying on a supplier certificate alone is indefensible for a product with a quantified label claim: the manufacturer owns the specification and must test identity, marker content, ash, moisture, heavy metals, microbial limits and pesticide residues on each lot, with periodic supplier audits and retained samples. The specification should be built around a marker profile (withanolide A and withaferin A, with a defined ratio band and a total) rather than a single number, and the label claim must match what the validated method measures. Given these results the batch should be rejected, and if earlier batches were released on CoA alone, a look-back and possible recall should be considered.